Bionode is innovating bioelectronic medical devices. The company’s primary focus is on delivering a device with the potential for regulating elevated intraocular pressure (IOP) in glaucoma. Glaucoma is the second leading cause of irreversible blindness, worldwide. The use of “electroceuticals” offers a higher degree of control over biological functions and disease states than pharmaceuticals, while avoiding unwanted side effects. It represents the ultimate in personalized medicine. Bionode has secured rights to a rich intellectual property portfolio, licensed out of the Purdue Research Foundation’s Office of Technology Commercialization. These underlying technologies, comprising the bionode platform, were invented by the company’s co-founder, Prof. Pedro Irazoqui and his team at the Center for Implantable Devices at Purdue University’s Weldon School of Biomedical Engineering. The IP of the company can be repurposed to address a range of other pathological conditions.